Geneva Biotech

Geneva Biotech is a privately held, platform-focused biotech company developing advanced DNA delivery technologies for gene therapy and complex cell engineering applications. Its core expertise lies in engineering viral vectors to overcome cargo size limitations and target difficult cell and organ types. The company utilizes its platforms both for internal drug discovery programs, as evidenced by its preclinical candidate GB-007, and for providing research tools and services to academic and industrial partners. With a seasoned leadership team and a foundation in cutting-edge viral vector engineering, Geneva Biotech is positioned at the intersection of gene delivery technology and therapeutic development.

Engineered viral vector systems for delivery of large, complex DNA cargos into diverse cell types (insect, mammalian, primary, iPS, neurons, tissues). Expertise includes viral genome engineering, pseudotyping, and novel cell entry strategies.

Geneva Biotech competes in the crowded gene delivery platform space, which includes companies focused on AAV engineering, lentiviral vectors, lipid nanoparticles, and other non-viral methods. Its key differentiator is a focus on very large cargo capacity and delivery into difficult primary cell types. For its internal drug candidate GB-007, it competes in the vast small molecule GPCR modulator market.